Gastroenterology
Volume 136, Issue 5 , Pages 1796-1805.e6 , May 2009

A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C

  • Hironobu Tsukada

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
    • Pharmacology Research Laboratories, Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd, Kasugade Naka, Konohana-ku, Osaka, Japan
    • ,
  • Hidenori Ochi

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
    • ,
  • Toshiro Maekawa

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
    • ,
  • Hiromi Abe

      Affiliations

    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
    • ,
  • Yoshifumi Fujimoto

      Affiliations

    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
    • ,
  • Masataka Tsuge

      Affiliations

    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
    • ,
  • Hiroshi Takahashi

      Affiliations

    • Laboratory for Statistical Analysis, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Shirokanedai, Minato-ku, Tokyo, Japan
    • ,
  • Hiromitsu Kumada

      Affiliations

    • Department of Hepatology, Toranomon Hospital, Toranomon, Minato-ku, Tokyo, Japan
    • ,
  • Naoyuki Kamatani

      Affiliations

    • Laboratory for Statistical Analysis, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Shirokanedai, Minato-ku, Tokyo, Japan
    • ,
  • Yusuke Nakamura

      Affiliations

    • Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan
    • ,
  • Kazuaki Chayama

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
    • Corresponding Author InformationReprint requests Address requests for reprints to: Kazuaki Chayama, MD, PhD, Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. fax: (81) 82-255-6220

Received 3 January 2008 ,Accepted 29 January 2009.

References 

  1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  2. Management of hepatitis C. NIH Consensus Statement 1997; available at http://consensus.nih.gov/1997/1997HepatitisC105html.htm.
  3. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296–305
  4. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22:1050–1056
  5. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat. 2000;7:250–257
  6. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55:529–535
  7. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 2004;39:880–890
  8. Huang Y, Yang H, Borg BB, et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A. 2007;104:985–990
  9. Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology. 2001;33:708–712
  10. Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol. 2005;40:381–388
  11. Suzuki F, Arase Y, Suzuki Y, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat. 2004;11:271–276
  12. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol. 2002;36:271–277
  13. Matsuyama N, Mishiro S, Sugimoto M, et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res. 2003;25:221–225
  14. Pharoah PD, Dunning AM, Ponder BA, et al. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850–860
  15. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet. 2001;29:233–237
  16. Gibbs RA, Belmont JW, Hardenbol P, et al. The International HapMap Project. Nature. 2003;426:789–796
  17. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421
  18. Uddin S, Lekmine F, Sharma N, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem. 2000;275:27634–27640
  19. Li Y, Batra S, Sassano A, et al. Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. J Biol Chem. 2005;280:10001–10010
  20. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem. 1999;274:30127–30131
  21. Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem. 2001;276:28570–28577
  22. Li Y, Sassano A, Majchrzak B, et al. Role of p38alpha Map kinase in type I interferon signaling. J Biol Chem. 2004;279:970–979
  23. Ishida H, Ohkawa K, Hosui A, et al. Involvement of p38 signaling pathway in interferon-alpha-mediated antiviral activity toward hepatitis C virus. Biochem Biophys Res Commun. 2004;321:722–727
  24. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med. 1994;39:241–275
  25. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection (Tokyo-Chiba Hepatitis Research Group). Gastroenterology. 1997;113:558–566
  26. Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol. 2005;40:381–388
  27. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–1520
  28. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32:650–654
  29. Ohnishi Y, Tanaka T, Ozaki K, et al. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet. 2001;46:471–477
  30. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003;34:395–402
  31. Iida A, Saito S, Sekine A, et al. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J Hum Genet. 2001;46:668–683
  32. Osawa N, Koya D, Araki S, et al. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet. 2007;52:143–151
  33. Kamiyama M, Kobayashi M, Araki SI, et al. Polymorphisms in the 3′ untranslated region in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy. Hum Genet. 2007;122:397–407
  34. Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet. 1998;63:1531–1540
  35. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881–885
  36. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics. 1995;29:311–322
  37. Freedman ML, Reich D, Penney KL, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet. 2004;36:388–393
  38. Sithanandam G, Latif F, Duh FM, et al. 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol. 1996;16:868–876
  39. Ludwig S, Engel K, Hoffmeyer A, et al. 3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol. 1996;16:6687–6697
  40. Neufeld B, Grosse-Wilde A, Hoffmeyer A, et al. Serine/threonine kinases 3pK and MAPK-activated protein kinase 2 interact with the basic helix-loop-helix transcription factor E47 and repress its transcriptional activity. J Biol Chem. 2000;275:20239–20242
  41. Maizels ET, Mukherjee A, Sithanandam G, et al. Developmental regulation of mitogen-activated protein kinase-activated kinases-2 and -3 (MAPKAPK-2/-3) in vivo during corpus luteum formation in the rat. Mol Endocrinol. 2001;15:716–733
  42. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–972
  43. Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002–1009
  44. Hoofnagle JH, Lau D, Conjeevaram H, et al. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat. 1996;3:247–252
  45. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225–2229

 Conflicts of interest The authors disclose no conflicts.

 Funding This study was supported by a grant from the Japanese Millennium Project, and in part by Dainippon Sumitomo Pharma Co, Ltd. This work was also supported in part by a Grant-in-Aid for Scientific Research and Development from the Ministry of Education, Sports, Culture, and Technology and the Ministry of Health, Labor, and Welfare.

PII: S0016-5085(09)00165-6

doi: 10.1053/j.gastro.2009.01.061

Gastroenterology
Volume 136, Issue 5 , Pages 1796-1805.e6 , May 2009

Article Tools

* Image Usage & Resolution